+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antibody Drug"

Biliary Tumor - Pipeline Insight, 2024 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2024

  • Clinical Trials
  • July 2024
  • 180 Pages
  • Global
From
From
From
From
Hepatic Tumor - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatic Tumor - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 240 Pages
  • Global
From
Anti-CD20 antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD20 antibody - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Nasopharyngeal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Nasopharyngeal Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Herpes Zoster - Pipeline Insight, 2024 - Product Thumbnail Image

Herpes Zoster - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 85 Pages
  • Global
From
Influenza - Pipeline Insight, 2024 - Product Thumbnail Image

Influenza - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 280 Pages
  • Global
From
Mesothelioma - Pipeline Insight, 2024 - Product Thumbnail Image

Mesothelioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 210 Pages
  • Global
From
Biliary Tract Cancer (BTC) - Pipeline Insight, 2024 - Product Thumbnail Image

Biliary Tract Cancer (BTC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 180 Pages
  • Global
From
HER2-positive Gastric Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

HER2-positive Gastric Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Testicular Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Testicular Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
H1N1 infection - Pipeline Insight, 2024 - Product Thumbnail Image

H1N1 infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Gastric Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Gastric Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 550 Pages
  • Global
From
Advanced Merkel cell carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Merkel cell carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Lyme Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Lyme Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Acquired Hemophilia A - Pipeline Insight, 2024 - Product Thumbnail Image

Acquired Hemophilia A - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 50 Pages
  • Global
From
Vulvar Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Vulvar Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 70 Pages
  • Global
From
Loading Indicator

The Antibody Drug market is a subset of the biotechnology industry that focuses on the development and commercialization of therapeutic antibodies. Antibody drugs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These drugs are designed to target specific molecules in the body, such as proteins, hormones, and enzymes, and can be used to block or activate certain pathways. Antibody drugs are typically administered intravenously or subcutaneously, and can be used in combination with other drugs or therapies. The Antibody Drug market is highly competitive, with many companies investing in research and development to create new and improved treatments. Companies in the market are focused on developing novel antibodies, as well as improving existing treatments. Additionally, companies are investing in the development of biosimilars, which are generic versions of existing antibody drugs. Some companies in the Antibody Drug market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi. Show Less Read more